ENSG00000141027 |
|
cecum adenocarcinoma |
missense_variant |
9.886% (26/263) |
1 entry |
ENSG00000141027 |
|
Breast Carcinoma by Gene Expression Profile |
sequence_alteration |
6.798% (86/1265) |
1 entry |
ENSG00000141027 |
|
breast ductal adenocarcinoma |
sequence_alteration |
6.424% (111/1728) |
2 entries |
ENSG00000141027 |
|
Breast Carcinoma by Gene Expression Profile |
frameshift_variant |
6.798% (86/1265) |
1 entry |
ENSG00000141027 |
|
colorectal adenocarcinoma |
frameshift_variant |
6.849% (80/1168) |
2 entries |
ENSG00000141027 |
|
breast ductal adenocarcinoma |
stop_gained |
6.424% (111/1728) |
2 entries |
ENSG00000141027 |
|
Breast Carcinoma by Gene Expression Profile |
stop_gained |
6.798% (86/1265) |
2 entries |
ENSG00000141027 |
|
breast ductal adenocarcinoma |
missense_variant |
6.424% (111/1728) |
1 entry |
ENSG00000141027 |
|
cecum adenocarcinoma |
frameshift_variant |
9.886% (26/263) |
1 entry |
ENSG00000141027 |
|
cecum adenocarcinoma |
stop_gained |
9.886% (26/263) |
2 entries |
ENSG00000141027 |
|
colorectal adenocarcinoma |
sequence_alteration |
6.849% (80/1168) |
1 entry |
ENSG00000141027 |
|
colorectal adenocarcinoma |
stop_gained |
6.849% (80/1168) |
4 entries |
ENSG00000141027 |
|
breast ductal adenocarcinoma |
frameshift_variant |
6.424% (111/1728) |
4 entries |
ENSG00000141027 |
|
Breast Carcinoma by Gene Expression Profile |
missense_variant |
6.798% (86/1265) |
4 entries |
ENSG00000141027 |
|
colorectal adenocarcinoma |
missense_variant |
6.849% (80/1168) |
4 entries |
ENSG00000141027 |
|
esophageal adenocarcinoma |
missense_variant |
8.044% (44/547) |
1 entry |
ENSG00000141027 |
|
oral squamous cell carcinoma |
sequence_alteration |
3.788% (10/264) |
1 entry |
ENSG00000141027 |
|
osteosarcoma |
sequence_alteration |
4.605% (7/152) |
2 entries |
ENSG00000141027 |
|
squamous cell lung carcinoma |
sequence_alteration |
2.468% (23/932) |
2 entries |
ENSG00000141027 |
|
small cell lung carcinoma |
missense_variant |
3.401% (15/441) |
3 entries |
ENSG00000141027 |
|
B-cell acute lymphoblastic leukemia |
missense_variant |
3.797% (6/158) |
4 entries |
ENSG00000141027 |
|
prostate carcinoma |
missense_variant |
4.194% (19/453) |
5 entries |
ENSG00000141027 |
|
Gallbladder Adenocarcinoma |
missense_variant |
5.488% (9/164) |
2 entries |
ENSG00000141027 |
|
lobular breast carcinoma |
frameshift_variant |
7.664% (21/274) |
1 entry |
ENSG00000141027 |
|
rectal adenocarcinoma |
frameshift_variant |
1.832% (10/546) |
1 entry |
ENSG00000141027 |
|
prostate adenocarcinoma |
stop_gained |
4.868% (105/2157) |
1 entry |
ENSG00000141027 |
|
Endometrial Endometrioid Adenocarcinoma |
stop_gained |
4.482% (29/647) |
1 entry |
ENSG00000141027 |
|
urothelial carcinoma |
missense_variant |
10.47% (9/86) |
1 entry |
ENSG00000141027 |
|
bronchoalveolar adenocarcinoma |
missense_variant |
13.64% (3/22) |
1 entry |
ENSG00000141027 |
|
prostate adenocarcinoma |
sequence_alteration |
4.868% (105/2157) |
3 entries |
ENSG00000141027 |
|
nasopharyngeal squamous cell carcinoma |
missense_variant |
2.222% (4/180) |
2 entries |
ENSG00000141027 |
|
acute lymphoblastic leukemia |
sequence_alteration |
1.869% (6/321) |
1 entry |
ENSG00000141027 |
|
HER2 Positive Breast Carcinoma |
frameshift_variant |
15.74% (17/108) |
1 entry |
ENSG00000141027 |
|
colon adenocarcinoma |
sequence_alteration |
4.984% (63/1264) |
5 entries |
ENSG00000141027 |
|
lung adenocarcinoma |
stop_gained |
2.204% (56/2541) |
2 entries |
ENSG00000141027 |
|
osteosarcoma |
missense_variant |
4.605% (7/152) |
1 entry |
ENSG00000141027 |
|
skin melanoma |
sequence_alteration |
4.996% (58/1161) |
2 entries |
ENSG00000141027 |
|
lobular breast carcinoma |
missense_variant |
7.664% (21/274) |
2 entries |
ENSG00000141027 |
|
squamous cell lung carcinoma |
missense_variant |
2.468% (23/932) |
3 entries |
ENSG00000141027 |
|
non-small cell lung carcinoma |
missense_variant |
3.125% (3/96) |
1 entry |
ENSG00000141027 |
|
papillary renal cell carcinoma |
missense_variant |
1.55% (6/387) |
1 entry |
ENSG00000141027 |
|
head and neck squamous cell carcinoma |
missense_variant |
2.937% (22/749) |
2 entries |
ENSG00000141027 |
|
basal cell carcinoma |
missense_variant |
13.24% (9/68) |
1 entry |
ENSG00000141027 |
|
laryngeal squamous cell carcinoma |
missense_variant |
7.317% (3/41) |
2 entries |
ENSG00000141027 |
|
prostate adenocarcinoma |
missense_variant |
4.868% (105/2157) |
2 entries |
ENSG00000141027 |
|
pharyngeal squamous cell carcinoma |
missense_variant |
3.704% (3/81) |
3 entries |
ENSG00000141027 |
|
acute lymphoblastic leukemia |
stop_gained |
1.869% (6/321) |
1 entry |
ENSG00000141027 |
|
esophageal squamous cell carcinoma |
sequence_alteration |
2.047% (14/684) |
2 entries |
ENSG00000141027 |
|
bladder transitional cell carcinoma |
sequence_alteration |
5.263% (30/570) |
3 entries |
ENSG00000141027 |
|
hepatocellular carcinoma |
missense_variant |
2.104% (21/998) |
2 entries |
ENSG00000141027 |
|
gastric adenocarcinoma |
sequence_alteration |
3.75% (27/720) |
2 entries |
ENSG00000141027 |
|
gastric adenocarcinoma |
stop_gained |
3.75% (27/720) |
1 entry |
ENSG00000141027 |
|
metaplastic breast carcinoma |
sequence_alteration |
4.839% (3/62) |
1 entry |
ENSG00000141027 |
|
bladder carcinoma |
sequence_alteration |
6.702% (38/567) |
1 entry |
ENSG00000141027 |
|
esophageal squamous cell carcinoma |
stop_gained |
2.047% (14/684) |
2 entries |
ENSG00000141027 |
|
rectal adenocarcinoma |
stop_gained |
1.832% (10/546) |
1 entry |
ENSG00000141027 |
|
HER2 Positive Breast Carcinoma |
missense_variant |
15.74% (17/108) |
1 entry |
ENSG00000141027 |
|
lung adenocarcinoma |
missense_variant |
2.204% (56/2541) |
6 entries |
ENSG00000141027 |
|
bladder carcinoma |
missense_variant |
6.702% (38/567) |
1 entry |
ENSG00000141027 |
|
Breast Carcinoma by Gene Expression Profile |
conservative_inframe_deletion |
6.798% (86/1265) |
1 entry |
ENSG00000141027 |
|
Endometrial Endometrioid Adenocarcinoma |
sequence_alteration |
4.482% (29/647) |
1 entry |
ENSG00000141027 |
|
papillary renal cell carcinoma |
sequence_alteration |
1.55% (6/387) |
1 entry |
ENSG00000141027 |
|
breast carcinoma |
sequence_alteration |
4.037% (69/1709) |
3 entries |
ENSG00000141027 |
|
gastric adenocarcinoma |
missense_variant |
3.75% (27/720) |
1 entry |
ENSG00000141027 |
|
melanoma |
sequence_alteration |
6.897% (10/145) |
1 entry |
ENSG00000141027 |
|
lung adenocarcinoma |
sequence_alteration |
2.204% (56/2541) |
3 entries |
ENSG00000141027 |
|
female breast carcinoma |
missense_variant |
3.901% (11/282) |
2 entries |
ENSG00000141027 |
|
rectal adenocarcinoma |
missense_variant |
1.832% (10/546) |
2 entries |
ENSG00000141027 |
|
pancreatic ductal adenocarcinoma |
missense_variant |
2.852% (48/1683) |
2 entries |
ENSG00000141027 |
|
small cell lung carcinoma |
sequence_alteration |
3.401% (15/441) |
3 entries |
ENSG00000141027 |
|
prostate carcinoma |
sequence_alteration |
4.194% (19/453) |
3 entries |
ENSG00000141027 |
|
endometrium adenocarcinoma |
frameshift_variant |
7.407% (2/27) |
1 entry |
ENSG00000141027 |
|
pancreatic ductal adenocarcinoma |
sequence_alteration |
2.852% (48/1683) |
1 entry |
ENSG00000141027 |
|
skin melanoma |
stop_gained |
4.996% (58/1161) |
2 entries |
ENSG00000141027 |
|
acute myeloid leukemia |
missense_variant |
2.478% (28/1130) |
1 entry |
ENSG00000141027 |
|
lobular breast carcinoma |
sequence_alteration |
7.664% (21/274) |
1 entry |
ENSG00000141027 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
missense_variant |
1.515% (4/264) |
2 entries |
ENSG00000141027 |
|
breast carcinoma |
missense_variant |
4.037% (69/1709) |
3 entries |
ENSG00000141027 |
|
oral squamous cell carcinoma |
missense_variant |
3.788% (10/264) |
4 entries |
ENSG00000141027 |
|
melanoma |
missense_variant |
6.897% (10/145) |
2 entries |
ENSG00000141027 |
|
chronic lymphocytic leukemia |
sequence_alteration |
1.684% (15/891) |
2 entries |
ENSG00000141027 |
|
bladder transitional cell carcinoma |
missense_variant |
5.263% (30/570) |
4 entries |
ENSG00000141027 |
|
urothelial carcinoma |
stop_gained |
10.47% (9/86) |
1 entry |
ENSG00000141027 |
|
Gallbladder Adenocarcinoma |
sequence_alteration |
5.488% (9/164) |
1 entry |
ENSG00000141027 |
|
bladder transitional cell carcinoma |
frameshift_variant |
5.263% (30/570) |
1 entry |
ENSG00000141027 |
|
T-cell acute lymphoblastic leukemia |
missense_variant |
1.305% (5/383) |
2 entries |
ENSG00000141027 |
|
breast carcinoma |
stop_gained |
4.037% (69/1709) |
3 entries |
ENSG00000141027 |
|
skin melanoma |
missense_variant |
4.996% (58/1161) |
6 entries |
ENSG00000141027 |
|
Endometrial Endometrioid Adenocarcinoma |
missense_variant |
4.482% (29/647) |
1 entry |
ENSG00000141027 |
|
Gallbladder Adenocarcinoma |
stop_gained |
5.488% (9/164) |
1 entry |
ENSG00000141027 |
|
breast carcinoma |
frameshift_variant |
4.037% (69/1709) |
2 entries |
ENSG00000141027 |
|
Merkel cell skin cancer |
missense_variant |
3.226% (3/93) |
2 entries |
ENSG00000141027 |
|
rectal adenocarcinoma |
sequence_alteration |
1.832% (10/546) |
1 entry |
ENSG00000141027 |
|
colon adenocarcinoma |
missense_variant |
4.984% (63/1264) |
8 entries |
ENSG00000141027 |
|
brain glioblastoma |
missense_variant |
1.155% (14/1212) |
2 entries |
ENSG00000141027 |
|
lung adenocarcinoma |
frameshift_variant |
2.204% (56/2541) |
2 entries |
ENSG00000141027 |
|
cecum adenocarcinoma |
sequence_alteration |
9.886% (26/263) |
1 entry |
ENSG00000141027 |
|
papillary thyroid carcinoma |
missense_variant |
0.409% (2/489) |
1 entry |
ENSG00000141027 |
|
colon adenocarcinoma |
frameshift_variant |
4.984% (63/1264) |
4 entries |
ENSG00000141027 |
|
clear cell renal carcinoma |
sequence_alteration |
0.8827% (14/1586) |
1 entry |
ENSG00000141027 |
|
clear cell renal carcinoma |
missense_variant |
0.8827% (14/1586) |
3 entries |
ENSG00000141027 |
|
pancreatic neuroendocrine tumor |
missense_variant |
6.78% (16/236) |
1 entry |
ENSG00000141027 |
|
lobular breast carcinoma |
stop_gained |
7.664% (21/274) |
2 entries |
ENSG00000141027 |
|
esophageal squamous cell carcinoma |
missense_variant |
2.047% (14/684) |
5 entries |
ENSG00000141027 |
|
prostate adenocarcinoma |
frameshift_variant |
4.868% (105/2157) |
1 entry |
ENSG00000141027 |
|
T-cell acute lymphoblastic leukemia |
stop_gained |
1.305% (5/383) |
1 entry |
ENSG00000141027 |
|
colon adenocarcinoma |
stop_gained |
4.984% (63/1264) |
5 entries |
ENSG00000141027 |
|
metaplastic breast carcinoma |
missense_variant |
4.839% (3/62) |
1 entry |
ENSG00000141027 |
|
bladder transitional cell carcinoma |
stop_gained |
5.263% (30/570) |
2 entries |
ENSG00000141027 |
|
hepatocellular carcinoma |
sequence_alteration |
2.104% (21/998) |
2 entries |
ENSG00000141027 |
|
female breast carcinoma |
frameshift_variant |
3.901% (11/282) |
1 entry |
ENSG00000141027 |
|
follicular thyroid carcinoma |
missense_variant |
2.899% (2/69) |
1 entry |
ENSG00000141027 |
|
gastric adenocarcinoma |
frameshift_variant |
3.75% (27/720) |
1 entry |
ENSG00000141027 |
|
acute lymphoblastic leukemia |
frameshift_variant |
1.869% (6/321) |
1 entry |
ENSG00000141027 |
|
squamous cell lung carcinoma |
stop_gained |
2.468% (23/932) |
1 entry |
ENSG00000141027 |
|
Appendix Adenocarcinoma |
missense_variant |
1.299% (1/77) |
1 entry |
ENSG00000141027 |
|
multiple myeloma |
missense_variant |
4.444% (2/45) |
1 entry |
ENSG00000141027 |
|
follicular thyroid carcinoma |
sequence_alteration |
2.899% (2/69) |
1 entry |
ENSG00000141027 |
|
small cell lung carcinoma |
stop_gained |
3.401% (15/441) |
1 entry |
ENSG00000141027 |
|
anaplastic oligodendroglioma |
missense_variant |
1.176% (1/85) |
1 entry |
ENSG00000141027 |
|
angiosarcoma |
missense_variant |
4.255% (2/47) |
1 entry |
ENSG00000141027 |
|
prostate carcinoma |
frameshift_variant |
4.194% (19/453) |
1 entry |
ENSG00000141027 |
|
urothelial carcinoma |
frameshift_variant |
10.47% (9/86) |
1 entry |
ENSG00000141027 |
|
ovarian serous adenocarcinoma |
missense_variant |
0.12% (1/833) |
1 entry |
ENSG00000141027 |
|
central nervous system primitive neuroectodermal neoplasm |
missense_variant |
0.6696% (3/448) |
1 entry |
ENSG00000141027 |
|
medullary thyroid gland carcinoma |
missense_variant |
2.778% (1/36) |
1 entry |
ENSG00000141027 |
|
Mixed Lobular and Ductal Breast Carcinoma |
missense_variant |
4.054% (3/74) |
1 entry |
ENSG00000141027 |
|
endometrium adenocarcinoma |
missense_variant |
7.407% (2/27) |
1 entry |
ENSG00000141027 |
|
Endometrial Clear Cell Adenocarcinoma |
missense_variant |
3.704% (1/27) |
1 entry |
ENSG00000141027 |
|
testicular seminoma |
sequence_alteration |
1.282% (1/78) |
1 entry |
ENSG00000141027 |
|
testicular seminoma |
missense_variant |
1.282% (1/78) |
1 entry |
ENSG00000141027 |
|
medullary thyroid gland carcinoma |
sequence_alteration |
2.778% (1/36) |
1 entry |
ENSG00000141027 |
|
clear cell renal carcinoma |
frameshift_variant |
0.8827% (14/1586) |
1 entry |
ENSG00000141027 |
|
gastric intestinal type adenocarcinoma |
frameshift_variant |
3.529% (3/85) |
1 entry |
ENSG00000141027 |
|
squamous cell lung carcinoma |
frameshift_variant |
2.468% (23/932) |
1 entry |
ENSG00000141027 |
|
Ampulla of Vater Carcinoma |
missense_variant |
1.176% (1/85) |
1 entry |
ENSG00000141027 |
|
Endometrial Endometrioid Adenocarcinoma |
frameshift_variant |
4.482% (29/647) |
1 entry |
ENSG00000141027 |
|
Merkel cell skin cancer |
sequence_alteration |
3.226% (3/93) |
1 entry |
ENSG00000141027 |
|
gastric intestinal type adenocarcinoma |
stop_gained |
3.529% (3/85) |
1 entry |
ENSG00000141027 |
|
Tracheal Squamous Cell Carcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000141027 |
|
Mixed Lobular and Ductal Breast Carcinoma |
frameshift_variant |
4.054% (3/74) |
1 entry |
ENSG00000141027 |
|
undifferentiated pleomorphic sarcoma |
missense_variant |
1.613% (1/62) |
1 entry |
ENSG00000141027 |
|
leiomyosarcoma |
stop_gained |
1.0% (1/100) |
1 entry |
ENSG00000141027 |
|
Merkel cell skin cancer |
stop_gained |
3.226% (3/93) |
1 entry |
ENSG00000141027 |
|
Pancreatic Acinar Cell Carcinoma |
missense_variant |
2.941% (1/34) |
1 entry |
ENSG00000141027 |
|
prostate adenocarcinoma |
conservative_inframe_deletion |
4.868% (105/2157) |
1 entry |
ENSG00000141027 |
|
skin carcinoma |
missense_variant |
8.654% (9/104) |
1 entry |
ENSG00000141027 |
|
Mixed Lobular and Ductal Breast Carcinoma |
stop_gained |
4.054% (3/74) |
1 entry |
ENSG00000141027 |
|
Mantle cell lymphoma |
conservative_inframe_deletion |
1.887% (1/53) |
1 entry |
ENSG00000141027 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
stop_gained |
1.515% (4/264) |
1 entry |
ENSG00000141027 |
|
female breast carcinoma |
stop_gained |
3.901% (11/282) |
1 entry |
ENSG00000141027 |
|
small intestinal adenocarcinoma |
missense_variant |
4.762% (1/21) |
1 entry |
ENSG00000141027 |
|
astrocytoma |
missense_variant |
16.67% (1/6) |
1 entry |
ENSG00000141027 |
|
Colorectal Neuroendocrine Tumor G1 |
stop_gained |
20.0% (1/5) |
1 entry |
ENSG00000141027 |
|
Fibroadenoma |
missense_variant |
1.408% (1/71) |
1 entry |
ENSG00000141027 |
|
brain glioblastoma |
sequence_alteration |
1.155% (14/1212) |
1 entry |
ENSG00000141027 |
|
Mantle cell lymphoma |
missense_variant |
1.887% (1/53) |
1 entry |
ENSG00000141027 |
|
mucosal melanoma |
missense_variant |
1.429% (1/70) |
1 entry |
ENSG00000141027 |
|
bile duct adenocarcinoma |
sequence_alteration |
0.5141% (2/389) |
1 entry |
ENSG00000141027 |
|
Anal Squamous Cell Carcinoma |
frameshift_variant |
1.22% (1/82) |
1 entry |
ENSG00000141027 |
|
colon carcinoma |
frameshift_variant |
12.5% (1/8) |
1 entry |
ENSG00000141027 |
|
basal cell carcinoma |
stop_gained |
13.24% (9/68) |
1 entry |
ENSG00000141027 |
|
salivary gland squamous cell carcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000141027 |
|
Peritoneal Mesothelioma |
frameshift_variant |
5.556% (1/18) |
1 entry |
ENSG00000141027 |
|
oligoastrocytoma |
missense_variant |
9.091% (1/11) |
1 entry |
ENSG00000141027 |
|
chromophobe renal cell carcinoma |
missense_variant |
0.6757% (1/148) |
1 entry |
ENSG00000141027 |
|
Endometrial Undifferentiated Carcinoma |
missense_variant |
33.33% (1/3) |
1 entry |
ENSG00000141027 |
|
Fibrolamellar Carcinoma |
frameshift_variant |
5.556% (1/18) |
1 entry |
ENSG00000141027 |
|
renal carcinoma |
missense_variant |
5.0% (1/20) |
1 entry |
ENSG00000141027 |
|
large cell lung carcinoma |
missense_variant |
5.263% (1/19) |
1 entry |
ENSG00000141027 |
|
Invasive Breast Carcinoma |
stop_gained |
2.222% (1/45) |
1 entry |
ENSG00000141027 |
|
Brain Stem Glioblastoma |
sequence_alteration |
1.786% (1/56) |
1 entry |
ENSG00000141027 |
|
angiosarcoma |
sequence_alteration |
4.255% (2/47) |
1 entry |
ENSG00000141027 |
|
salivary gland carcinoma |
stop_gained |
3.03% (1/33) |
1 entry |
ENSG00000141027 |
|
Parathyroid Gland Carcinoma |
stop_gained |
2.857% (1/35) |
1 entry |
ENSG00000141027 |
|
basal cell carcinoma |
sequence_alteration |
13.24% (9/68) |
1 entry |
ENSG00000141027 |
|
urothelial carcinoma |
conservative_inframe_deletion |
10.47% (9/86) |
1 entry |
ENSG00000141027 |
|
Testicular Embryonal Carcinoma |
conservative_inframe_deletion |
4.762% (1/21) |
1 entry |
ENSG00000141027 |
|
brain astrocytoma |
missense_variant |
2.083% (1/48) |
1 entry |
ENSG00000141027 |
|
Sinonasal Undifferentiated Carcinoma |
missense_variant |
8.333% (1/12) |
1 entry |
ENSG00000141027 |
|
diffuse large B-cell lymphoma |
stop_gained |
0.5405% (2/370) |
1 entry |
ENSG00000141027 |
|
bile duct adenocarcinoma |
missense_variant |
0.5141% (2/389) |
1 entry |
ENSG00000141027 |
|
soft tissue sarcoma |
amino_acid_insertion |
0.3413% (1/293) |
1 entry |
ENSG00000141027 |
|
pancreatic ductal adenocarcinoma |
frameshift_variant |
2.852% (48/1683) |
1 entry |
ENSG00000141027 |
|
colon adenocarcinoma |
conservative_inframe_deletion |
4.984% (63/1264) |
1 entry |
ENSG00000141027 |
|
medulloblastoma |
sequence_alteration |
4.167% (1/24) |
1 entry |
ENSG00000141027 |
|
multiple myeloma |
stop_gained |
4.444% (2/45) |
1 entry |
ENSG00000141027 |
|
rectal adenocarcinoma |
conservative_inframe_deletion |
1.832% (10/546) |
1 entry |
ENSG00000141027 |
|
Ovarian Carcinosarcoma |
missense_variant |
8.333% (1/12) |
1 entry |
ENSG00000141027 |
|
anaplastic astrocytoma |
missense_variant |
0.7692% (1/130) |
1 entry |
ENSG00000141027 |
|
breast carcinoma |
conservative_inframe_deletion |
4.037% (69/1709) |
1 entry |
ENSG00000141027 |
|
chronic myelomonocytic leukemia |
missense_variant |
3.704% (1/27) |
1 entry |
ENSG00000141027 |
|
Salivary Gland Carcinoma ex Pleomorphic Adenoma |
frameshift_variant |
4.167% (1/24) |
1 entry |
ENSG00000141027 |
|
large cell medulloblastoma |
frameshift_variant |
5.263% (1/19) |
1 entry |
ENSG00000141027 |
|
brain glioblastoma |
frameshift_variant |
1.155% (14/1212) |
1 entry |
ENSG00000141027 |
|
head and neck squamous cell carcinoma |
sequence_alteration |
2.937% (22/749) |
1 entry |
ENSG00000141027 |
|
pulmonary blastoma |
frameshift_variant |
4.167% (1/24) |
1 entry |
ENSG00000141027 |
|
gastric intestinal type adenocarcinoma |
missense_variant |
3.529% (3/85) |
1 entry |
ENSG00000141027 |
|
neoplasm |
missense_variant |
6.897% (2/29) |
1 entry |
ENSG00000141027 |
|
Duodenal Adenocarcinoma |
stop_gained |
5.882% (1/17) |
1 entry |
ENSG00000141027 |
|
prostate carcinoma |
conservative_inframe_deletion |
4.194% (19/453) |
1 entry |
ENSG00000141027 |
|
Gastric Neuroendocrine Tumor G1 |
missense_variant |
11.11% (1/9) |
1 entry |
ENSG00000141027 |
|
Appendix Goblet Cell Carcinoid |
missense_variant |
4.762% (1/21) |
1 entry |
ENSG00000141027 |
|
adrenocortical adenoma |
missense_variant |
2.439% (1/41) |
1 entry |
ENSG00000141027 |
|
benign blood vessel neoplasm |
missense_variant |
25.0% (1/4) |
1 entry |
ENSG00000141027 |
|
laryngeal squamous cell carcinoma |
stop_gained |
7.317% (3/41) |
1 entry |
ENSG00000141027 |
|
chondroblastoma |
sequence_alteration |
14.29% (1/7) |
1 entry |
ENSG00000141027 |
|
Adrenal Gland Neuroblastoma |
missense_variant |
1.667% (1/60) |
1 entry |
ENSG00000141027 |
|
B-cell acute lymphoblastic leukemia |
sequence_alteration |
3.797% (6/158) |
1 entry |